Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy Concurrently published results from the

The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterprise Includes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering 1 in 3 Americans – nearly 110 million lives Initial focus will be on EQRx’s two lead oncology

Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery network Potential to provide access to affordable treatments in areas of high-cost burden for more than 1 million people within Geisinger health systems CAMBRIDGE, Mass., Jan.

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that Melanie Nallicheri, chief executive officer, will present